Transcend: A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

IRB Number: STU00201825
ClinicalTrials.gov Identifier: NCT02631044
PI Name: Leo Gordon
Eligibility Criteria:

  • Participants must have any of the following types of lymphoma: Diffuse Large B-cell Lymphoma – DLBCL; Transformed DLBCL from indolent histology; Follicular Lymphoma Grade 3B; Mantle Cell Lymphoma.
  • Participants must have cancer that has returned or has not responded to other treatment.
  • Participants must be 18 or older.

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Leo I. Gordon, MD

Leo I. Gordon, MD

Primary Specialty: Hematology and Medical Oncology


Platform: An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies

IRB Number: STU00206138
ClinicalTrials.gov Identifier: NCT03310619
PI Name: Reem Karmali
Eligibility Criteria:

  • Participants must have a confirmed diagnosis of Relapsed/Refractory B-Cell Malignancies

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Reem Karmali, MD

Reem Karmali, MD

Primary Specialty: Hematology and Medical Oncology


Transcend CLL: An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

IRB Number: STU00208648
ClinicalTrials.gov Identifier: NCT03331198
PI Name: Shuo Ma
Eligibility Criteria:

  • Participants must have any of the following types of lymphoma: Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
  • You must have received 2 or 3 prior treatments for your CLL or SLL
  • Participants must have cancer that has returned or has not responded to other treatment.
  • Participants must be 18 or older.

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Shuo Ma, MD, PhD

Shuo Ma, MD, PhD

Primary Specialty: Hematology and Medical Oncology


UCART123-01: Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia

IRB Number: STU00213504
ClinicalTrials.gov Identifier: NCT03190278
PI Name: Shira Dinner
Eligibility Criteria: patients must have a diagnosis of Relapsed/Refractory Acute Myeloid Leukemia with >5% bone marrow blasts AND must have received:

  • at least 2 cycles of therapy with at least 1 regimen of anthracycline + cytarabine OR
  • at least 1 cycle of a high- or intermediate-dose cytarabine containing regimen OR
  • at least 4 cycles of hypomethylating agent (HMA) as single agent or 2 cycles of HMA as part of combination therapy OR
  • ASCT for either AML or high-risk MDS, off immune-suppression and without GVHD OR
  • R/R disease without established alternative therapy

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Shira N. Dinner, MD

Shira N. Dinner, MD

Primary Specialty: Hematology and Medical Oncology


KarMMa-3: A Phase 3, Multicenter, Randomized, Open- Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)

IRB Number: STU00208507
ClinicalTrials.gov Identifier: NCT03651128
PI Name: Leo Gordon
Eligibility Criteria:

  • Documented diagnosis of Multiple Myeloma and measurable disease
  • Able to understand the nature of this trial and provide written informed consent; 3)
  • Participants must be 18 or older.

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Leo I. Gordon, MD

Leo I. Gordon, MD

Primary Specialty: Hematology and Medical Oncology


Cartitude-2: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2)

IRB Number: STU00210994
ClinicalTrials.gov Identifier: NCT04133636
PI Name: Seema Singhal
Eligibility Criteria:

  • Participants must have a diagnosis of multiple myeloma
  • Participants must be 18 or older.

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Seema Singhal, MD

Seema Singhal, MD

Primary Specialty: Hematology


Transcend FL: A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) 

IRB Number: STU00212069
ClinicalTrials.gov Identifier: NCT04245839
PI Name: Reem Karmalil
Eligibility Criteria: Age of at least 18 years. Diagnosis of Follicular or Marginal Zone Lymphoma, which has either returned or is not responding to your current treatment. Follicular Lymphoma and Marginal Zone Lymphoma are two types of non-Hodgkin lymphoma (NHL). Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.

For more information, read the study details on clinicaltrials.gov.

Principal Investigator

Reem Karmali, MD

Reem Karmali, MD

Primary Specialty: Hematology and Medical Oncology